Search clinical trials for: Docetaxel (Taxotere®)

Total 15863 results

Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc

Completed

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic

Vietnam
Nanogen Pharmaceutical Biotechnology Joint Stock...
Vietstar Biomedical Research; MedProve Inc

Completed

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Breast Cancer Recurrent | Breast Cancer Female | Breast Cancer Metastatic

Vietnam
SCRI Development Innovations, LLC
Aventis Pharmaceuticals; Sanofi-Synthelabo

Completed

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

Esophagus Cancer

United States
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA)

Metastatic Breast Cancer

United States, Canada, China, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Spain, United Kingdom, Brazil, Guatemala, Japan, Russian Federation, Singapore, Thailand, Latvia, Argentina, Poland, Ecuador, Mexico, Croatia and more
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (TAPIS)

HNSCC

France
University of Miami

Terminated

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Head and Neck Cancer | Recurrent Disease | Squamous Cell Carcinoma

United States
Danish Breast Cancer Cooperative Group
Sanofi; Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning; Dako

Completed

Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer (READ)

Breast Neoplasms

Denmark
NewLink Genetics Corporation

Completed

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Poland
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Seagen Inc.

Completed

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

Prostatic Neoplasms

United States
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Lung Cancer

United States
Dutch Society of Physicians for Pulmonology and...

Completed

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) (NVALT10)

Carcinoma, Non-Small-Cell Lung

Netherlands
The University of Texas Health Science Center at...

Terminated

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Stanford University

Completed

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Head and Neck Cancer

United States
University of Cincinnati

Terminated

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Australia, China, Korea, Republic of, Denmark, Germany, Greece, Russian Federation, Hungary, France, New Zealand, Spain, Austria, Slovakia, United Kingdom, Malaysia, Lithuania, South Africa, Slovenia, Italy, Canada, Belgium, Poland, Czech Republic and more
Wolfgang Hilbe
Sanofi; Merck Sharp & Dohme LLC; TAKO - Tiroler Arbeitskreis Onkologie

Completed

Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-small-cell Lung

Austria
Baylor Breast Care Center
Baylor College of Medicine

Completed

Biologic Correlative Taxotere/AC (TAX/AC)

Breast Cancer

United States
Jules Bordet Institute
Sanofi

Terminated

Early Cardiac Toxicity of Adjuvant CT in Elderly BC.

Breast Cancer

Belgium
The Methodist Hospital Research Institute
Merck Sharp & Dohme LLC

Suspended

Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (INTEGRAL)

Triple Negative Breast Cancer | Anthracycline-refractory TNBC

United States
ETOP IBCSG Partners Foundation
Biodesix, Inc.

Completed

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. (EMPHASIS)

Carcinoma, Non-Small-Cell Lung

Ireland, Switzerland, Denmark, Spain, United Kingdom, Belgium, Hungary, Greece, Israel, Austria, Italy, Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Nerium Biotechnology

Withdrawn

Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer | Chemotherapeutic Agent Toxicity
Stanford University
Aventis Pharmaceuticals

Terminated

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

Carcinoma, Non-Small-Cell Lung | Lung Cancer

United States
Groupe Français de Pneumo-Cancérologie
Sanofi; Chugai Pharma USA

Completed

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

France
Fudan University

Unknown

Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer

Nasopharyngeal Carcinoma

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Shanghai Zhongshan Hospital

Enrolling by invitation

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

Gastric Cancer

China
University of Michigan Rogel Cancer Center

Completed

A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer

Head and Neck Cancer

United States
M.D. Anderson Cancer Center
Aventis Pharmaceuticals

Completed

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Metastatic Melanoma

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Breast Cancer

China
University of Southern California
Novartis; Genentech, Inc.

Completed

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Prostate Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
OHSU Knight Cancer Institute
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Terminated

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
Mirati Therapeutics Inc.
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)

Metastatic Non-Squamous Non-Small Cell Lung Cancer

United States, Canada, Belgium, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
G1 Therapeutics, Inc.

Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (PRESERVE 4)

NSCLC | Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
Novartis

Completed

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Sun Yat-sen University
Chinese Southwest Oncology Group

Unknown

Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Pfizer

Completed

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Breast Cancer

Belgium, Italy
Peking Union Medical College Hospital

Unknown

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

Non Small Cell Lung Cancer

China
Shanghai Jiao Tong University School of Medicine
Fudan University; Qilu Hospital of Shandong University

Recruiting

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis

Prostate Cancer Patients

China
US Oncology Research
Sanofi

Completed

Adj TC + Herceptin Early Stage Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Sanofi

Completed

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Lung Cancer

United States
Korean Breast Cancer Study Group

Unknown

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer (NeoTG)

Breast Cancer Stage II | Breast Cancer Stage III

Korea, Republic of
Qilu Pharmaceutical Co., Ltd.

Completed

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Breast Cancer

China

Search clinical trials for: Docetaxel (Taxotere®)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations